Online inquiry

IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4993MR)

This product GTTS-WQ4993MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGA2B&ITGB3 gene. The antibody can be applied in Platelet aggregation research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000419.5; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3674; 3690
UniProt ID P08514; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4993MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15669MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ7998MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ5238MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ9584MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ4766MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ9697MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ15065MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ891MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW